A clinical and pharmacologic study of the combination of erlotinib and bexarotene in resectable clinical stage I-II non-small cell lung cancer.

Trial Profile

A clinical and pharmacologic study of the combination of erlotinib and bexarotene in resectable clinical stage I-II non-small cell lung cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Bexarotene (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Feb 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 08 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top